Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
3期
已完成
NCT03999996
| 适应症 | Dengue Fever |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Takeda |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 365 人 |
|---|
| 干预（药物） | Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) |
|---|
| 开始日期 | 2019年11月12日 |
|---|
| 完成日期 | 2024年5月25日 |
|---|
| 结果公布日 | 2025年6月12日 |
|---|
摘要
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-304 (NCT03423173) (United States \[US\]) and to describe the impact of a tetravalent dengue vaccine (TDV) booster dose vs placebo on antibody response for each of the 4 dengue serotypes at 1 month and 6 months post administration of the TDV booster or placebo.
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])
Month 0 (Day 1) · titer
| Prior to Booster: DEN-304 | 76.8 titer |
|---|
| Prior to Booster: DEN-315 | 88.6 titer |
|---|
| Prior to Booster: DEN-304 | 539.6 titer |
|---|
| Prior to Booster: DEN-315 | 425.6 titer |
|---|
| Prior to Booster: DEN-304 | 33.7 titer |
|---|
| Prior to Booster: DEN-315 | 29.5 titer |
|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)
Month 12 · titer
| Prior to Booster: DEN-304 | 58.4 titer |
|---|
| Prior to Booster: DEN-315 | 96.4 titer |
|---|
| Prior to Booster: DEN-304 | 427.3 titer |
|---|
| Prior to Booster: DEN-315 | 276.1 titer |
|---|
| Prior to Booster: DEN-304 | 32.8 titer |
|---|
| Prior to Booster: DEN-315 | 25.3 titer |
|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)
Month 15 (DEN-304) · titer
| Prior to Booster: DEN-304 | 121.7 titer |
|---|
| Prior to Booster: DEN-304 | 560.2 titer |
|---|
| Prior to Booster: DEN-304 | 40.3 titer |
|---|
| Prior to Booster: DEN-304 | 37.6 titer |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。